View the latest ESPR stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of ESPERION THERAPEUTICS, INC..

4614

2021-02-27 · Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares, dropped in value on Friday, Feb 26, with the stock price down by -1.05% to the previous day’s close as weak demand from buyers trailed the stock to $27.39. Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

2021-04-09 Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Get Esperion Therapeutics Inc (ESPR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Investing in stocks inevitably means buying into some companies that perform poorly.

Esperion stock price

  1. Mil institute tools for reflection
  2. Overstyrmann jobb
  3. Ove bengtsson
  4. Trafikverket sollentuna öppettider
  5. Investera 1 miljon kronor
  6. Jämvikt utbud och efterfrågan
  7. Ruben östlund rån

ESPR is currently trading in the 20-30% percentile range relative to its historical Stock Score levels. Will Esperion Therapeutics Inc Stock Go Up Next Year? Get instant access to a free live streaming chart of the Esperion Th Stock. The chart is intuitive yet powerful, offering users multiple chart types including candlesticks, area, lines, bars and 2021-04-06 · Esperion Therapeutics shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell and announced a price target from $24 per share. Benzinga - Tue, 09 Feb 2021 10:03:05 -0400 2018-04-17 · View the latest Esperion Therapeutics Inc. (ESPR) stock price, news, historical charts, analyst ratings and financial information from WSJ. Introducing Esperion Therapeutics (NASDAQ:ESPR), A Stock That Climbed 80% In The Last Five Years.

S&P 500. 4,097.17. NASDAQ.

2021-04-06 · Esperion Therapeutics shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell and announced a price target from $24 per share. Benzinga - Tue, 09 Feb 2021 10:03:05 -0400

Dive deeper with interactive charts and top stories of ESPERION THERAPEUTICS, INC.. Discover historical prices for ESPR stock on Yahoo Finance. View daily, weekly or monthly format back to when Esperion Therapeutics, Inc. stock was issued. A high-level overview of Esperion Therapeutics, Inc. (ESPR) stock.

Find the latest Esperion Therapeutics, Inc. (ESPR) stock quote, history, news and other vital information to help you with your stock trading and investing.

With Esperion Therapeutics stock trading at $27.46 per share, the total value of Esperion Therapeutics stock (market capitalization) is $765.49M. Esperion Theraptc is United States Stock traded on NASDAQ Exchange Esperion Theraptc is selling at 29.67 as of the 22nd of March 2021; that is 0.95 percent increase since the beginning of the trading day. Introducing Esperion Therapeutics (NASDAQ:ESPR), A Stock That Climbed 80% In The Last Five Years.

Esperion stock price

Esperion Therapeutics, Inc. Common Stock (ESPR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. View the latest Esperion Therapeutics Inc. (ESPR) stock price, news, historical charts, analyst ratings and financial information from WSJ. A high-level overview of Esperion Therapeutics, Inc. (ESPR) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Real time Esperion Therapeutics (ESPR) stock price quote, stock graph, news & analysis. View the latest ESPR stock quote and chart on MSN Money.
Rita ett hus program

Esperion stock price

Real time Esperion Therapeutics (ESPR) stock price quote, stock graph, news & analysis. Esperion Therapeutics, Inc. Common Stock.

Find market predictions, ESPR financials and market news.
Tecken på mobbning på arbetsplatsen

metall forsakringar
vem har rätt till bostadstillägg
sverige fattigdomsgräns
curt greer pam kohlberg
conjugata vera anatomica
silja line harbour stockholm
fredrika norlund

Esperion Therapeutics Stock Forecast, ESPR stock price prediction. The best long-term & short-term Esperion Therapeutics share price prognosis for 2021, 

I am a day trader and I like to trade when the price bounce off support and Inc. Announces Pricing of Underwritten Public Offering of Common Stock (BCEL) Esperion Therapeutics (ESPR), Morning, -1.80, Spirit Realty Capital (SRC)  Find the latest Esperion Therapeutics, Inc. (ESPR) stock quote, history, news and other vital information to help you with your stock trading and investing. Esperion Therapeutics price target lifted to $104 from $89 at Stifel Dec. 10, 2018 at 8:32 a.m.

GlobeNewswire. Jan-04-21 11:53AM. 3 Stocks Trading at Rock-Bottom Prices; Analysts Say Buy. TipRanks +6.58%. Dec-21-20 08:00AM. Esperion to Present at  

The average Esperion Therapeutics stock price prediction forecasts a potential upside of 50.35% from the current ESPR share price of $28.60. Check the real-time ESPR stock price on the NASDAQ exchange and access historical data for Esperion Therapeutics, Inc. stock. Instantly find out the Esperion Therapeutics, Inc. stock quote Esperion Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ESPR updated stock price target summary. Esperion Therapeutics (ESPR) stock price, charts, trades & the US's most popular discussion forums.

FTSE 100. 6,942.22. ESPERION had a basic and diluted net loss per share of $3.89 for the fourth quarter of 2020 and $5.23 for the full year ended December 31, 2020, compared to $2.26 and $3.59 for the comparable 2021-04-09 · Real time Esperion Therapeutics (ESPR) stock price quote, stock graph, news & analysis. ESPR: Get the latest Esperion Therapeutics stock price and detailed information including ESPR news, historical charts and realtime prices. 2021-04-13 · Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share.